| 15.30 – 15.40 | Welcome & Introduction Stefan Lethagen, Sobi™, Sweden |
| 15.40 – 15.50 | Retrospective real world analysis of haemophilia A patients with inhibitors treated with rFVIIIFc for immune tolerance induction Jennifer Dumont, Bioverativ™, USA |
| 15.50 – 16.05 | Elucidating rFVIIIFc interactions with the immune system Katalin Kis-Toth, Bioverativ™ USA |
| 16.05 – 16.20 | MHC class II presentation of Fc Tregitope and FVIII epitopes in rFVIIIFc: Potential implications for tolerance Margareta Wikén, Sobi™, Sweden |
| 16.20 – 16.30 | Q&A Session and closing remarks Stephen James, Sobi™, Sweden |